Session Details
Oral Session 13 Treatment Strategies for Unresectable and Recurrent Colorectal Cancer 1
Fri. Nov 20, 2026 12:50 PM - 1:50 PM JST
Fri. Nov 20, 2026 3:50 AM - 4:50 AM UTC
Fri. Nov 20, 2026 3:50 AM - 4:50 AM UTC
Room 6 (1F 103)
座長：平田 賢郎（慶應義塾大学病院 腫瘍センター）
[O13-1]Current Status and Challenges of Postoperative ctDNA Testing in Resectable Colorectal Cancer: A Real-World Clinical Practice Study
*Yuko Fukumoto1 (1. Division of lower GI, Department of Gastroenterological surgery, Hyogo Medical University)
[O13-2]AZD6738 Enhances the Antitumor Effect of FTD in 5-FU–Resistant Colorectal Cancer Cell Lines
*Shuhei Uehara1 (1. Department of Gastroenterological Surgery, Graduate School of Medicine, Nagoya City University)
[O13-3]Clinical Outcomes of Immune Checkpoint Inhibitor Therapy for Unresectable Advanced or Recurrent MSI-H/dMMR Colorectal Cancer
*Sho Nambara1 (1. Department of Surgery and Science, Graduate School of Medical Science, Kyushu University)
[O13-4]Retreatment with Anti-EGFR Antibody-Based Regimens in Later-Line Therapy for Unresectable Advanced or Recurrent Colorectal Cancer: A Case Series of Eight Patients
*Norihito Ishida1 (1. Department of Gastroenterology and Hepatology, Keio University Hospital)
[O13-5]Influence of Age on Outcomes of FOLFIRI Plus Ramucirumab: A Subgroup Analysis of the RINDO study
*Hiroyasu Yamamoto1 (1. Department of Surgery, Nagoya University Graduate School of Medicine)
[O13-6]Encorafenib and cetuximab with or without binimetinib treatment for metastatic colorectal cancer with BRAF V600E mutation
*Kaoru Abe1 (1. Department of Surgery,Niigata Cancer Center Hospital)
[O13-7]Challenges in Interpreting ERBB2 Equivocal Results in Colorectal Cancer
*Shinji Furuya1 (1. First Department of Surgery, Faculty of Medicine, University of Yamanashi)
[O13-8]Pembrolizumab treatment outcomes for MSI-H advanced/recurrent colorectal cancer.
*Kazuko Yokota1 (1. Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine)